Psyched Wellness Raises $6.6 Million In Bought Deal Financing

Psyched Wellness (CSE: PSYC) has closed its previously announced private placement. The company managed to raise an impressive $6.6 million under the financing, a sizeable increase from the initial $3.0 million that was to be raised under the financing.

The offering saw a total of 21.3 million units of the company sold at a price of $0.31 per unit. Each unit consists of one common share and one common share purchase warrant, with each warrant valid for a period of three years from the date of issuance with an exercise price of $0.43 per share.

Warrants issued under the offering are also subject to an acceleration clause, whereby the company can accelerate the expiry if the equity trades above $0.70 for a period of five days on a volume weighted basis.

Proceeds from the offering are to be used to fully fund the pre-clinical trials of the firms proprietary amanita muscaria extract, known as AME-1, as well as to continue researching the compound and its potential for people suffering from mental and physical health issues. Proceeds are also to be used for general corporate purposes.

Psyched Wellness last traded at $0.55 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Tudor Gold x American Creek: Consolidating A Massive Gold Project

Aura Minerals: The Era Dorada Underground PEA

Gold Is Now Smart Money’s End Game | Doug Casey

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Psyched Wellness Completes First Step In Study Identifying Potential Of Muscimol

Psyched Wellness (CSE: PSYC) has completed the first step in identifying the medicinal potential of...

Thursday, January 14, 2021, 06:58:13 AM

Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the...

Thursday, October 7, 2021, 08:21:06 AM

Psyched Wellness Increases Bought Deal To $5.5 Million

Psyched Wellness (CSE: PSYC) has increased the size of its bought deal private placement as...

Monday, January 25, 2021, 07:09:05 AM

Psyched Wellness Sees Positive Results From Amanita Muscaria Toxicology Report

Psyched Wellness (CSE: PSYC) has completed its toxicology assessment on that of Amanita Muscaria, the...

Monday, December 7, 2020, 07:56:50 AM

Daily Dive: Shroom Stocks About To Fly? With Jeff Stevens, CEO Of Psyched Wellness

Today on The Daily Dive we have Jeff Stevens, CEO of Psyched Wellness (CSE: PSYC)....

Monday, November 9, 2020, 01:00:00 PM